Related Experiment Videos
[Field trial with a new betablocker (Solgol)]
MMW, Munchener Medizinische Wochenschrift
|October 17, 1980
Summary
Nadolol effectively lowers blood pressure in hypertensive patients, with 59.5% achieving normal ranges. This beta-blocker demonstrates good tolerance and a long half-life, making it a viable treatment option.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Hypertension management requires effective and well-tolerated antihypertensive medications.
- Beta-blockers are a cornerstone of cardiovascular therapy, but individual agent efficacy and side effect profiles vary.
Purpose:
- To evaluate the efficacy and tolerance of nadolol in a large cohort of unselected hypertensive patients.
- To assess nadolol's effectiveness in patients switching from other antihypertensive drugs and beta-blockers.
Summary:
- A field trial involving 14,870 hypertensive patients demonstrated that nadolol lowered blood pressure into the normal range in 59.5% of participants.
- Optimal blood pressure control was achieved with daily doses of 60-240 mg in 32.4% of patients, with 87% responding to 60-120 mg daily.
- Nadolol showed significant diastolic blood pressure reduction (77% of patients) and maintained efficacy across age groups, unlike other beta-blockers. Its long half-life (20-24 hours) and good tolerance were noted.
Impact:
- Nadolol presents a valuable therapeutic option for hypertension, particularly for patients requiring effective diastolic pressure control and those switching from other medications.
- The drug's sustained action and favorable side effect profile contribute to improved patient adherence and long-term management of hypertension.